1. Home
  2. MGY vs ACAD Comparison

MGY vs ACAD Comparison

Compare MGY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnolia Oil & Gas Corporation

MGY

Magnolia Oil & Gas Corporation

N/A

Current Price

$23.93

Market Cap

4.8B

Sector

Energy

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$18.16

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MGY
ACAD
Founded
2017
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.4B
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
MGY
ACAD
Price
$23.93
$18.16
Analyst Decision
Buy
Buy
Analyst Count
20
20
Target Price
★ $32.82
$30.53
AVG Volume (30 Days)
★ 2.7M
2.5M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
★ 3.03%
N/A
EPS Growth
N/A
★ 69.12
EPS
0.24
★ 0.51
Revenue
★ $1,311,845,000.00
$726,437,000.00
Revenue This Year
$58.77
$19.43
Revenue Next Year
$34.33
$13.21
P/E Ratio
$98.71
★ $36.08
Revenue Growth
N/A
★ 40.45
52 Week Low
$21.07
$15.86
52 Week High
$32.76
$30.96

Technical Indicators

Market Signals
Indicator
MGY
ACAD
Relative Strength Index (RSI) 44.01 38.95
Support Level $23.40 N/A
Resistance Level $27.79 $22.71
Average True Range (ATR) 0.81 1.10
MACD -0.20 -0.11
Stochastic Oscillator 39.96 34.91

Price Performance

Historical Comparison
MGY
ACAD

About MGY Magnolia Oil & Gas Corporation

Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area of South Texas, where it targets the Eagle Ford Shale and Austin Chalk formations. It focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its capital spending philosophy. The company operates in only one segment and derives the majority of its revenue from the sale of crude oil, natural gas, and natural gas liquids (NGLs).

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: